Colivelin: ADNF–Humanin Hybrid Neuropeptide, Femtomolar STAT3 Activation, and Neuroprotection Against Alzheimer’s Disease and ALS in Research Models

Colivelin: ADNF–Humanin Hybrid Neuropeptide, Femtomolar STAT3 Activation, and Neuroprotection Against Alzheimer’s Disease and ALS in Research Models Research Article | Neuropeptide Pharmacology, Alzheimer’s Disease & Neuroprotection Abstract & Overview Colivelin (CLN; C₁₁₉H₂₀₆N₃₂O₃₅; MW 2645.10 g/mol; CAS 867021-83-8) is a synthetic 26-amino-acid hybrid neuropeptide engineered by the laboratory of Ikuo Nishimoto at Keio University School of Medicine, Tokyo, Japan. It was designed by fusing the N-terminus of activity-dependent neurotrophic factor (ADNF), a femtomolar-acting neuroprotective peptide, to the C-terminus of AGA-(C8R)HNG17, a 17-amino-acid derivative of the mitochondrial peptide humanin (HN) that is 10⁵ times more potent than the parent molecule. The resulting fusion peptide achieves complete neuroprotection at concentrations as low as 100 femtomolar (fM) in vitro — a potency approximately 10⁷ times greater than original humanin and among the highest reported for any synthetic neuroprotective peptide [1][2]. Colivelin’s primary mechanism of action involves potent activation of STAT3 (Signal Transducer and Activator of Transcription 3) through the JAK2/STAT3 prosurvival signalling cascade, a pathway originally identified as the central mediator of humanin’s neuroprotective activity. In addition, Colivelin activates CaM kinase IV (CaMKIV), a calcium/calmodulin-dependent serine-threonine kinase critical for synaptic plasticity and memory consolidation. Together, these two pathways converge to suppress neuronal apoptosis induced by Alzheimer’s disease (AD)-related insults including amyloid-β (Aβ) peptides, familial AD-linked V642I-APP mutation, and ALS-related mutant superoxide dismutase (SOD1). Preclinical research has further demonstrated that intranasally administered Colivelin reaches the CNS via the olfactory bulb and dose-dependently ameliorates memory impairment in AD mouse models [2][3][4]. “A 26-amino-acid peptide colivelin (CL), composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R)-HNG17, provides complete neuroprotection at 100-femtomolar or higher concentrations in vitro. A series of experiments using mouse AD and ALS models further established the efficacy of HN derivatives, including CL, against these diseases in vivo. HN and CL can be viewed as drug candidates for neuronal death suppression therapy in AD or ALS.” — Matsuoka, Hashimoto, Aiso & Nishimoto. CNS Drug Rev. 2006;12(2):113–122 [4]. Beyond its established neurological research applications, more recent investigations have identified Colivelin’s cytoprotective properties in non-neuronal contexts. Urban et al. (2022) demonstrated that Colivelin treatment ameliorated endothelial injury, glycocalyx shedding, and organ damage in a murine sepsis model, with the mechanism in this context involving AMPK activation and context-dependent STAT3 modulation — highlighting the compound’s broader cytoprotective versatility across disease states [5]. Colivelin is currently classified as a research-use-only compound with no approved clinical applications, though its exceptional potency and brain-penetrant properties position it as a compelling subject for future translational research in neurodegenerative disease. Molecular Identity and Structural Architecture The Humanin Foundation: Mitochondrial Origin and STAT3 Signalling To understand Colivelin’s design rationale, it is essential to appreciate the foundational biology of humanin (HN), the 24-amino-acid mitochondrial peptide from which it is derived. Humanin was originally identified in 2001 by Hashimoto et al. from a cDNA library constructed from the occipital lobe of an autopsied Alzheimer’s disease patient, where it was found to suppress neuronal death induced by AD-relevant insults including Aβ peptides, familial AD gene mutations (V642I-APP, N141I-PS2, M146L-PS1), and the anti-AD drug FK506 [6]. Humanin is encoded within the 16S ribosomal RNA gene of the mitochondrial genome, making it a member of the emerging class of mitochondrial-derived peptides (MDPs) — small peptides translated from short open reading frames within mitochondrial DNA that exert cytoprotective effects in the cytoplasm and extracellular space [6][7]. Humanin’s neuroprotective mechanism operates through binding to a cell-surface receptor complex comprising the cytokine receptor subunits gp130 and CNTFRα, and the IL-6 receptor-related component WSX-1 (also known as IL-27Rα). Receptor engagement activates the Janus kinase 2 (JAK2)/STAT3 prosurvival signalling cascade, which drives the transcription of anti-apoptotic genes including Bcl-2 and Bcl-xL while suppressing pro-apoptotic signals mediated by IGFBP3 and TRAF2. Despite its compelling neuroprotective profile, native humanin has significant pharmacological limitations: its effective concentration in vitro is in the nanomolar range, and its 24-amino-acid linear structure renders it susceptible to rapid proteolytic degradation in bio

For research use only. Not for human consumption.